SecBot SecBot
PRESS-RELEASE ·Filed Apr 27, 2026

IRTC

iRhythm
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

These data strengthen iRhythm’s clinical differentiation and could accelerate adoption in high-value settings like post-ablation monitoring and prenatal cardiology. Traders should monitor for follow-up publications, payer coverage changes, or new clinical guidelines incorporating extended monitoring, which could drive volume and revenue growth.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$125.96
T+0 close · Apr 27, 2026 · via day close
Latest settled
−15.79%
T+60 · $106.07
Vs SPY
−20.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $125.96entry
  2. T+1 · 7mo ago −0.41%α +0.07% · $125.44
  3. T+5 · 7mo ago −5.38%α −5.78% · $119.18
  4. T+20 · 6mo ago −9.14%α −14.09% · $114.45
  5. T+60 · 4mo ago −15.79%α −20.57% · $106.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

iRhythm (IRTC) presented new real-world data at HRS 2026 showing that 26% of atrial fibrillation (AF) recurrences after ablation and 60% of clinically significant arrhythmias in pregnant patients are missed with standard 24–48-hour Holter monitoring, reinforcing the clinical advantage of its 14-day Zio ambulatory ECG monitoring. The findings support broader adoption of extended monitoring to improve diagnosis, anticoagulation decisions, and maternal care.

Key Facts

  • 26% of AF recurrences after ablation were detected beyond 48 hours, meaning short-term monitoring would misclassify up to 1 in 4 patients as false negatives.
  • 60% of clinically significant arrhythmias in pregnant patients were first detected after 48 hours, with 13.6% having such events.
  • Study included 11,051 post-ablation patients and 486 pregnant women monitored via Zio devices.
  • 99.2% median analyzable time in pregnancy study confirms high data quality with Zio monitoring.
  • Data challenge clinical validity of trials like OCEAN that rely on 24–48-hour monitoring for anticoagulation decisions.

Financial Impact

Potential revenue upside from increased adoption in post-ablation and obstetric cardiology markets; no direct financial figures disclosed.

revenuemarket shareclinical adoption

Risk Factors

  • Market adoption may lag despite strong evidence due to entrenched use of Holter monitors.
  • Reimbursement constraints for extended monitoring in pregnancy or post-ablation settings could limit commercial impact.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3281593

Track record

31 reports on IRTC

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.85% at T+60 after the Feb 25, 2026 report. 10 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $90.12 Now $90.83 +0.79% settles Nov 23
  2. Nov 13, 20263d ago 8-K Neutral 2/10 Entry $91.91 Now $90.83 −1.18% settles Nov 20
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $93.56 Now $90.83 −2.92% settles Nov 19
  4. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $93.56 Now $90.83 −2.92% settles Nov 19
  5. Nov 11, 20265d ago Press Release Neutral 3/10 Entry $93.56 Now $90.83 −2.92% settles Nov 19
  6. Nov 5, 202611d ago 8-K Mixed 6/10 No price data
  7. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $90.22 to $91.91 Now $90.83 +0.68% ▲ +1.87% −0.72% vs SPY
  8. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $123.99 to $134.00 Now $90.83 −26.74% ▲ +8.07% +8.79% vs SPY
  9. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $108.66 Now $90.83 −16.41% No price data
  10. Oct 13, 20264w ago SC 13G/A Neutral 2/10 Entry $106.05 to $113.55 Now $90.83 −14.35% ▲ +7.07% +6.62% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens in 6h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026